Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health www.cancer.gov

Navigation

Personal tools

You are here: Home / Protocols / Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase II
Not an EDRN Protocol

Clinical Proteomic Technologies for Cancer Initiative (CPTAC) Phase II

1015
Kinsinger, ChrisNational Cancer Institute

No involved investigator sites defined.

The objective of the "System Suitability (CompRef) Study" was to validate mass spectrometry protocols used at each Proteome Characterization Center (PCC).

There are currently no biomarkers annotated for this protocol.

No datasets are currently associated with this protocol.


Announcement 09/14/2014

Thank you to everyone who helped make the 9th EDRN Scientific Workshop a success. We look forward to seeing everyone at the 28th EDRN Steering Committee Meeting from March 31-April 2, 2015, in Atlanta, GA.

Announcement 06/05/2014


Funding Opportunity Available

Both RFAs for Molecular and Cellular Characterization of Screen-Detected Lesions have been published.

RFA-CA-14-010.html

and

RFA-CA-14-011.html